Indaptus Therapeutics, Inc.
INDPNext catalyst
Decoy20
Solid Tumor, Adult
Get an email about INDP's next catalysts
Track Indaptus Therapeutics (INDP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
INDP Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Decoy20 Phase 2 Est. Readout
Primary completion for Decoy20 trial (NCT05651022) in Solid Tumor, Adult
SourceHow INDP's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Decoy20 | Phase 2 | Solid Tumor, Adult | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Indaptus Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Indaptus Therapeutics, Inc.'s (INDP) pipeline across Phase 2. Its lead program is Decoy20 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Indaptus Therapeutics, Inc.'s next FDA catalyst?→
Indaptus Therapeutics, Inc.'s (INDP) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INDP biotech catalysts?→
Add INDP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Indaptus Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.